498 Volunteers pre-screened for presence of *Plasmodium falciparum*

Excluded: 340
- Non-infected 254
- Refused to continue 44
- lost contact 42

151 Volunteers infected with *Plasmodium falciparum* screened for eligibility

Excluded: 84
- Abnormal chemistry or hematology 8
- HIV positive 6
- HbsAg positive 15
- HCV positive 4
- Abnormal ECG 1
- Refused to participate 9
- Scheduling conflict 8
- lost contact 12
- Other reasons: 21
Eligible but not enrolled: 08

Single dose study
40 participants enrolled and randomized

- 400 mg Single Dose (N=8 randomized)
  - 6 participants received 4 FQ capsules
  - 2 participants received 4 placebo matched capsules

- 800 mg Single Dose (N=8 randomized)
  - 6 participants received 8 FQ capsules
  - 2 participants received 8 placebo matched capsules

  Discontinued Follow up: 1 FQ (Patient request, Day 21)

- 1200 mg Single Dose (N=8 randomized)
  - 6 participants received 12 FQ capsules
  - 2 participants received 12 placebo matched capsules

  Discontinued Follow up: 1 FQ (Patient request, Day 36)

- 1400 mg Single Dose (N=8 randomized)
  - 6 participants received 14 FQ capsules
  - 2 participants received 14 placebo matched capsules

  Discontinued Follow up: 1 FQ (Lost to Follow-up, Day 53)

- 1600 mg Single Dose (N=8 randomized)
  - 6 participants received 16 FQ capsules
  - 2 participants received 16 placebo matched capsules

Repeated dose study
26 participants enrolled and randomized

- 400 mg 3-Day Repeated Dose (N=8 randomized)
  - 6 participants received 2 FQ capsules
  - 2 participants received 2 placebo matched capsules

  Discontinued Follow up: 1 FQ (Migration, Day 48)

- 600 mg 3-Day Repeated Dose (N=8 randomized)
  - 6 participants received 3 FQ capsules
  - 2 participants received 3 placebo matched capsules

  Discontinued Follow up: 1 FQ (Poor compliance, Day 36)
  1 placebo (Migration, Day 58)

- 800 mg 3 Day Repeated Dose (N=8 randomized)
  - 6 participants received 4 FQ capsules
  - 2 participants received 4 placebo matched capsules

- 1000 mg 3 Day Repeated Dose (N=2 randomized)
  - 1 participant received 5 FQ capsules
  - 1 participant received 5 placebo matched capsules

  Discontinued Follow up: 1 FQ (Migration, Day 6)

Excluded: 84
- Abnormal chemistry or hematology 8
- HIV positive 6
- HbsAg positive 15
- HCV positive 4
- Abnormal ECG 1
- Refused to participate 9
- Scheduling conflict 8
- lost contact 12
- Other reasons: 21
Eligible but not enrolled: 08